Skip to main content
SpringerLink
Log in

Clinical Trials Report

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organization and the International Society of Hypertension: Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens 1997, 15:105–115.

    Google Scholar 

  2. Piller LB, Davis BR, Cutler JA, et al.: Validation of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants assigned to doxazosin and chlorthalidone. Curr Control Trials Cardiovasc Med 2002, 3:10.

    Article  PubMed  Google Scholar 

  3. Saunders E, Weir MR, Kong BW, et al.: A comparison of the efficacy ad safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990, 150:1707–1713.

    Article  PubMed  CAS  Google Scholar 

  4. Materson BJ, Reda DJ, Cushman WC, et al.: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The department of Veterans Affairs Cooperative Study Group on antihypertensive agents. N Engl J Med 1993, 328:914–921.

    Article  PubMed  CAS  Google Scholar 

  5. Hansson L, Lindholm LH, Ekbom T, et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751–1756.

    Article  PubMed  CAS  Google Scholar 

  6. Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23(Suppl 2):B54-B64.

    PubMed  Google Scholar 

  7. Pahor M, Psaty BM, Alderman MH, et al.: Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000, 356:1949–1954.

    Article  PubMed  CAS  Google Scholar 

  8. Neal B, MacMahon S, Chapman N, Blood Pressure Lowering Treatment Trialists’ Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000, 356:1955–1964.

    Article  PubMed  CAS  Google Scholar 

  9. Chrysant SG, Weder AB, McCarron DA, et al.: Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. MIST II Trial Investigators. Am J Hypertens 2000, 13:1180–1188.

    Article  PubMed  CAS  Google Scholar 

  10. Flack JM, Mensah GA, Ferrario CM: Using angiotensin converting enzyme inhibitors in African-American hypertensives: a new approach to treating hypertension and preventing target-organ damage. Curr Med Res Opin 2000, 16:66–79.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. John M. Flack MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samar A. Nasser PAC
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Flack, J.M., Nasser, S.A. Clinical Trials Report. Current Science Inc 5, 189–191 (2003). https://doi.org/10.1007/s11906-003-0019-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-003-0019-8

Keywords

Search

Navigation